PURPOSE: This study was conducted to assess the prevalence and associated factors of nonproliferative diabetic retinopathy among type 2 diabetic patients in Kinmen, Taiwan. METHODS: From 1991 to 1993, 971 type 2 diabetic patients in Kinmen underwent diabetic retinopathy screening performed by a panel of ophthalmologists using indirect ophthalmoscopy and 45 degrees color fundus retinal photographs. RESULTS: Of the 971 patients screened in 1991-1993, 578 (59.5%) were examined for this study. Diabetic retinopathy was diagnosed in 127 patients (22.0%), including nonproliferative diabetic retinopathy in 13.3%, proliferative diabetic retinopathy in 1.4%, legal blindness in 1.4%, and ungradable diabetic retinopathy in 5.9%. Significant associated factors of nonproliferative diabetic retinopathy based on multiple logistic regression analysis were fasting plasma glucose (FPG) at baseline [> or =126 mg/dl vs. <126 mg/dl; odds ratio (OR) = 2.89; 95% confidence interval (CI), 1.01-9.09], 2-h postload at baseline (> or =200 vs. <200 mg/dl; OR = 1.48; 95% CI, 1.09-2.07); HbA1c at follow-up (> or =7% vs. <7%; OR = 6.54; 95% CI, 3.01-14.20), duration of diabetes (> or =15 years vs. <10 years; OR = 6.72; 95% CI, 2.13-21.18), and incremental systolic blood pressure between baseline and follow-up (OR = 1.02; 95% CI, 1.00-1.04). CONCLUSIONS: In addition to the longer duration of type 2 diabetes, FPG at baseline, poorly controlled glucose concentration, and altered blood pressure may increase the risk of nonproliferative diabetic retinopathy in type 2 diabetic patients. Copyright Japanese Ophthalmological Society 2006.
PURPOSE: This study was conducted to assess the prevalence and associated factors of nonproliferative diabetic retinopathy among type 2 diabeticpatients in Kinmen, Taiwan. METHODS: From 1991 to 1993, 971 type 2 diabeticpatients in Kinmen underwent diabetic retinopathy screening performed by a panel of ophthalmologists using indirect ophthalmoscopy and 45 degrees color fundus retinal photographs. RESULTS: Of the 971 patients screened in 1991-1993, 578 (59.5%) were examined for this study. Diabetic retinopathy was diagnosed in 127 patients (22.0%), including nonproliferative diabetic retinopathy in 13.3%, proliferative diabetic retinopathy in 1.4%, legal blindness in 1.4%, and ungradable diabetic retinopathy in 5.9%. Significant associated factors of nonproliferative diabetic retinopathy based on multiple logistic regression analysis were fasting plasma glucose (FPG) at baseline [> or =126 mg/dl vs. <126 mg/dl; odds ratio (OR) = 2.89; 95% confidence interval (CI), 1.01-9.09], 2-h postload at baseline (> or =200 vs. <200 mg/dl; OR = 1.48; 95% CI, 1.09-2.07); HbA1c at follow-up (> or =7% vs. <7%; OR = 6.54; 95% CI, 3.01-14.20), duration of diabetes (> or =15 years vs. <10 years; OR = 6.72; 95% CI, 2.13-21.18), and incremental systolic blood pressure between baseline and follow-up (OR = 1.02; 95% CI, 1.00-1.04). CONCLUSIONS: In addition to the longer duration of type 2 diabetes, FPG at baseline, poorly controlled glucose concentration, and altered blood pressure may increase the risk of nonproliferative diabetic retinopathy in type 2 diabeticpatients. Copyright Japanese Ophthalmological Society 2006.
Authors: C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: J A Pugh; J M Jacobson; W A Van Heuven; J A Watters; M R Tuley; D R Lairson; R J Lorimor; A S Kapadia; R Velez Journal: Diabetes Care Date: 1993-06 Impact factor: 19.112
Authors: J M Fairchild; S J Hing; K C Donaghue; M A Bonney; A T Fung; M M Stephens; P Mitchell; N J Howard; M Silink Journal: Med J Aust Date: 1994-06-20 Impact factor: 7.738
Authors: Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri Journal: Diabetes Res Clin Pract Date: 1995-05 Impact factor: 5.602
Authors: S M Haffner; D Fong; M P Stern; J A Pugh; H P Hazuda; J K Patterson; W A van Heuven; R Klein Journal: Diabetes Date: 1988-07 Impact factor: 9.461
Authors: Glen Y Ozawa; Marcus A Bearse; Kevin W Bronson-Castain; Wendy W Harrison; Marilyn E Schneck; Shirin Barez; Anthony J Adams Journal: Invest Ophthalmol Vis Sci Date: 2012-05-17 Impact factor: 4.799